类风湿关节炎患者带状疱疹疫苗的成本效益
该研究用决策分析马尔可夫模型评估类风湿关节炎(RA)患者接种重组带状疱疹疫苗(RZV)与不接种相比的成本效益。模型模拟10 000例RA患者终生结局,结果显示接种可减少带状疱疹(HZ)和带状疱疹后神经痛(PHN)病例,增量成本效益比(ICER)为11 205欧元/QALY,低于23 650欧元/QALY的阈值。
要点
- RA患者接种RZV可减少HZ和PHN病例,ICER为11 205欧元/QALY。
- 在23 650欧元/QALY阈值下,RZV具有成本效益的概率为98%。
- 结果对PHN发生概率的变化尤其敏感。
核心结论
- RA患者接种RZV与不接种相比健康获益更好但成本更高,在假设下可能具有成本效益。
研究设计与样本
- 研究采用决策分析马尔可夫模型,设定无HZ、HZ、PHN、HZ恢复和死亡五个健康状态。
- 模型随访10 000例RA假设队列的终生结局,从医疗保健角度记录HZ和PHN事件、QALYs和成本。
- 成本和健康效应按每年4%贴现,模型输入来自已发表文献和公开来源。
主要发现
- 每10 000例接种RZV的RA患者减少2 550例HZ和1 303例PHN。
- 接种RZV的ICER为11 205欧元/QALY。
- 单因素敏感性分析显示结果对PHN发生概率的变化尤其敏感。
- 概率分析显示在假设阈值23 650欧元/QALY下RZV具有成本效益的概率为98%。
关键数值与推荐
- 成本效益阈值设为23 650欧元/QALY。
- ICER为11 205欧元/QALY,低于上述阈值。
临床怎么用
- 在假设的阈值下,RA患者接种RZV可能被考虑为具有成本效益的干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the cost-effectiveness of vaccinating patients with rheumatoid arthritis (RA) with the adjuvanted recombinant zoster vaccine (RZV), compared with no vaccination. METHODS: To predict health gains and costs from vaccination, we developed a decision-analytic Markov model with five health states: no herpes zoster, herpes zoster (HZ), postherpetic neuralgia (PHN), recovered from HZ and death. The model follows a hypothetical cohort of 10 000 patients with RA over a lifetime perspective and records events of HZ and PHN, along with quality-adjusted life years (QALYs) and costs from a healthcare perspective. Costs and health effects were discounted with 4% annually. Model inputs were collected from published literature and publicly available sources. Cost-effectiveness was evaluated using the incremental cost-effectiveness ratio (ICER), expressed as EUR per QALY, compared with a cost-effectiveness threshold of EUR 23 650 per QALY. We performed one-way and probabilistic sensitivity analyses. RESULTS: Vaccination led to a reduction of 2550 cases of HZ and 1303 cases of PHN per 10 000 patients with RA vaccinated, resulting in an ICER of EUR 11 205/QALY. One-way sensitivity analyses revealed that the results were particularly sensitive to changes in the probability of developing PHN as a sequela of HZ. The probabilistic analysis indicated that the RZV had a 98% probability of being cost-effective at the assumed threshold value. CONCLUSION: Vaccinating patients with RA using RZV results in better health at higher cost compared with no vaccination. Under the assumptions made, vaccination is likely to be considered cost-effective for patients with RA.
引用
- Hagen G, Opheim AK, Overbo J, et al. Cost-effectiveness of herpes zoster vaccination in patients with rheumatoid arthritis. Rheumatology (Oxford). 2026. PMID: 42616666. doi:10.1093/rheumatology/keag448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。